secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001171843-24-005975
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q3: ORLADEYO revenue $116.3M (+35.7%); raises FY total revenue guide to $443-448M
--------------------------------------------------------------------------------

- Q3 total revenue $117.1M (+35.1% yoy) led by ORLADEYO net revenue of $116.3M.
- GAAP operating profit of $7.7M vs. loss of $11.9M in Q3 2023; non-GAAP op. profit $24.9M.
- Net loss narrowed to $14.0M ($0.07 per share) from $36.1M ($0.19) a year ago.
- FY 2024 ORLADEYO revenue guidance raised to $430-435M (top end of prior range); total revenue $443-448M.
- Pipeline: BCX17725 for Netherton syndrome entered clinic; avoralstat for DME on track for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324005975/0001171843-24-005975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324005975/f8k_110424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer